Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

13.3%

4 terminated/withdrawn out of 30 trials

Success Rate

86.7%

+0.2% vs industry average

Late-Stage Pipeline

63%

19 trials in Phase 3/4

Results Transparency

19%

5 of 26 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 3

11(42.3%)

Phase 4

8(30.8%)

Phase 2

4(15.4%)

Phase 1

2(7.7%)

N/A

1(3.8%)

26Total

Phase 3(11)

Phase 4(8)

Phase 2(4)

Phase 1(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials

NCT05544695Completed

Real-world Evidence Study on Cystistat

Role: lead

NCT05637515Phase 3Completed

Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity

Role: collaborator

NCT06126952Phase 2Completed

Azelastine Allergen Chamber - Onset of Action Study

Role: lead

NCT05158972Completed

Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients

Role: collaborator

NCT04652245Phase 4Completed

Dymista Allergen Chamber - Onset of Action Study

Role: lead

NCT01720407Phase 3Completed

Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face

Role: collaborator

NCT03004131Phase 4Completed

MP-AzeFlu Allergen Chamber - Onset of Action Study

Role: lead

NCT03599791Phase 3Completed

DYmista NAsal Spray in CHInese Patients

Role: lead

NCT00189280Phase 3Completed

Aldara for the Treatment of Large and/or Multiple sBCC

Role: lead

NCT00120523Phase 3Completed

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Role: lead

NCT01256086Phase 2Completed

Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg

Role: lead

NCT00328601Phase 3Completed

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)

Role: lead

NCT00761371Phase 4Completed

Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients

Role: lead

NCT00189267Phase 2Completed

A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients

Role: lead

NCT01336530Phase 3Terminated

Tepilta® Versus Oxetacaine, Antacids and Placebo

Role: lead

NCT00189319Phase 4Completed

To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation

Role: lead

NCT00977483Phase 3Completed

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)

Role: lead

NCT00408473Phase 4Terminated

Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.

Role: lead

NCT00189254Completed

A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

Role: lead

NCT00189293Phase 4Completed

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

Role: lead